Dupont Capital Management Corp Has $16.46 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Dupont Capital Management Corp boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,927 shares of the company's stock after purchasing an additional 1,283 shares during the period. Eli Lilly and Company accounts for approximately 1.8% of Dupont Capital Management Corp's portfolio, making the stock its 14th biggest position. Dupont Capital Management Corp's holdings in Eli Lilly and Company were worth $16,458,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of LLY. GAMMA Investing LLC boosted its position in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares during the last quarter. Norges Bank acquired a new stake in Eli Lilly and Company during the fourth quarter valued at $8,407,908,000. Proficio Capital Partners LLC boosted its position in Eli Lilly and Company by 100,387.1% during the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after purchasing an additional 5,197,038 shares during the last quarter. Wellington Management Group LLP boosted its position in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares during the last quarter. Finally, Capital International Investors boosted its position in Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on LLY shares. UBS Group reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price on the stock. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Guggenheim restated a "buy" rating and set a $936.00 target price on shares of Eli Lilly and Company in a report on Friday. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.79.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $21.61 during trading on Friday, reaching $763.43. The company's stock had a trading volume of 6,197,089 shares, compared to its average volume of 3,667,759. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a market cap of $723.53 billion, a price-to-earnings ratio of 62.12, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The business's fifty day moving average price is $780.48 and its 200-day moving average price is $801.13. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period last year, the business earned $2.58 earnings per share. The firm's quarterly revenue was up 45.2% compared to the same quarter last year. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.